These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 8907299

  • 1. Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood.
    Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM.
    Thromb Res; 1996 Feb 15; 81(4):491-6. PubMed ID: 8907299
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.
    Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM.
    Blood Coagul Fibrinolysis; 1998 Oct 15; 9(7):571-80. PubMed ID: 9863704
    [Abstract] [Full Text] [Related]

  • 4. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor.
    Jesty J, Lorenz A, Rodriguez J, Wun TC.
    Blood; 1996 Mar 15; 87(6):2301-7. PubMed ID: 8630391
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
    Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J.
    Thromb Res; 1994 Sep 15; 75(6):609-16. PubMed ID: 7831680
    [Abstract] [Full Text] [Related]

  • 6. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J, Lindblad B, Bergqvist D, Hedner U, Nordfang O, Ostergaard P.
    Thromb Res; 1997 May 15; 86(4):343-8. PubMed ID: 9187023
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
    Rao LV, Ruf W.
    Biochemistry; 1995 Aug 29; 34(34):10867-71. PubMed ID: 7662667
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
    Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J.
    Thromb Res; 1993 Mar 01; 69(5):443-52. PubMed ID: 8388583
    [Abstract] [Full Text] [Related]

  • 11. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
    Norrheim L, Abildgaard U, Larsen ML, Lindahl AK.
    Thromb Res Suppl; 1991 Mar 01; 14():19-27. PubMed ID: 1658967
    [Abstract] [Full Text] [Related]

  • 12. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, Bick RL.
    Semin Thromb Hemost; 2004 Feb 01; 30 Suppl 1():89-104. PubMed ID: 15085470
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding.
    Nagakura T, Tabata K, Kira K, Hirota S, Clark R, Matsuura F, Hiyoshi H.
    Thromb Res; 2013 Aug 01; 132(2):271-9. PubMed ID: 23827699
    [Abstract] [Full Text] [Related]

  • 15. Tissue factor pathway inhibitor (TFPI)--an update.
    Sandset PM.
    Haemostasis; 1996 Oct 01; 26 Suppl 4():154-65. PubMed ID: 8979119
    [Abstract] [Full Text] [Related]

  • 16. Heparin blunts endotoxin-induced coagulation activation.
    Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B.
    Circulation; 1996 Oct 01; 100(25):2485-90. PubMed ID: 10604885
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New data on the pharmacology of heparin and low molecular weight heparins.
    Samama MM, Bara L, Gouin-Thibault I.
    Drugs; 1996 Oct 01; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
    Mousa SA, Mohamed S.
    Thromb Haemost; 2004 Sep 01; 92(3):627-33. PubMed ID: 15351861
    [Abstract] [Full Text] [Related]

  • 20. Preclinical studies on a low molecular weight heparin.
    Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A.
    Thromb Res; 1996 Sep 01; 81(2 Suppl):S1-27. PubMed ID: 8822124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.